UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 236

Sortiert nach

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Circulation (New York, N.Y.), 2013-11, Vol.128 (19), p.2113-2120

2013

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1489-1499

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)

The American journal of cardiology, 2017-01, Vol.119 (1), p.40-46

2017

Link zum Volltext

Verfügbarkeit prüfen

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340

2015

Link zum Volltext

Verfügbarkeit prüfen

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment

Annals of medicine (Helsinki), 2023-12, Vol.55 (1), p.2199218-2199218

2023

Link zum Volltext

Verfügbarkeit prüfen

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096

2016

Link zum Volltext

Verfügbarkeit prüfen

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Link zum Volltext

Verfügbarkeit prüfen

An unusual case of hypercholesterolaemia with liver dysfunction

JEMDSA : the journal of endocrinology, metabolism and diabetes of South Africa, 2020-08, Vol.25 (2), p.31-35

2020

Link zum Volltext

Verfügbarkeit prüfen

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Nature reviews cardiology, 2023-12, Vol.20 (12), p.845-869

2023

Link zum Volltext

Verfügbarkeit prüfen

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

International journal of cardiology, 2014-02, Vol.171 (3), p.309-325

2014

Link zum Volltext

Verfügbarkeit prüfen

Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies

Atherosclerosis, 2018-10, Vol.277, p.502-507

2018

Link zum Volltext

Verfügbarkeit prüfen

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2010-03, Vol.375 (9719), p.998-1006

2010

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study

PloS one, 2014-08, Vol.9 (8), p.e102830-e102830

2014

Link zum Volltext

Verfügbarkeit prüfen

Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis

Current atherosclerosis reports, 2019-11, Vol.21 (12), p.48-48, Article 48

2019

Link zum Volltext

Verfügbarkeit prüfen

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

Journal of Atherosclerosis and Thrombosis, 2016/05/02, Vol.23(5), pp.567-587

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Journal of clinical medicine, 2023-08, Vol.12 (15), p.5082

2023

Link zum Volltext

Verfügbarkeit prüfen

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

The lancet. Diabetes & endocrinology, 2016-05, Vol.4 (5), p.403-410

2016

Link zum Volltext

Verfügbarkeit prüfen

Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials

Arteriosclerosis, thrombosis, and vascular biology, 2015-03, Vol.35 (3), p.689

2015

Link zum Volltext

Verfügbarkeit prüfen

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations

PloS one, 2020-02, Vol.15 (2), p.e0229098-e0229098

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations

PloS one, 2021-03, Vol.16 (3), p.e0249478-e0249478

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(221)
Mit Volltextzugriff
(211)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Life Sciences & Biomedicine
(158)
Humans
(131)
Female
(82)
Cardiovascular System & Cardiology
(78)
Male
(78)
Cardiac & Cardiovascular Systems
(67)
Adult
(58)
Middle Aged
(54)
Cholesterol
(51)
Cholesterol, Ldl - Blood
(43)
Hyperlipoproteinemia Type Ii - Genetics
(43)
Anticholesteremic Agents - Therapeutic Use
(38)
Adolescent
(34)
Treatment Outcome
(33)
Cardiovascular Disease
(32)
Hyperlipoproteinemia Type Ii - Drug Therapy
(31)
Peripheral Vascular Disease
(31)
Lipids
(30)
Biological And Medical Sciences
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

An unusual case of hypercholesterolaemia with liver dysfunction

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study

Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations

Suchergebnisse filtern